Questions | Multiple-choice responses | All, n (%) | CC, n (%) | UH, n (%) | GH, n (%) |
N=38 | N=10 | N=12 | N=16 | ||
1. Do you have any preference in the schedule of ICI choice for the treatment of CPs? | ☐ Yes, I prefer the schedule with the shorter interval | 4 (10.5) | 0 (0) | 3 (25) | 1 (6.3) |
☐ Yes, I prefer the schedule with the longer interval | 18 (47.4) | 6 (60) | 5 (41.7) | 7 (43.8) | |
☐ No, the schedule interval is not a criteria for ICI choice in my clinical practice | 16 (42.1) | 4 (40) | 4 (33.3) | 8 (50) | |
2. Do you have currently (during COVID-19 pandemic) any preference in the schedule of ICIs for the treatment of CPs? | ☐ Yes, I prefer the schedule with the shorter interval | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
☐ Yes, I prefer the schedule with the longer interval | 28 (73.7) | 7 (70) | 8 (66.7) | 13 (81.3) | |
☐ No, the schedule interval is not a criteria for ICI choice in my current clinical practice | 10 (26.3) | 3 (30) | 4 (33.3) | 3 (18.8) | |
3. Have you modified the dose of steroids you give in case of ICI adverse events? | ☐ Yes, I have reduced the dose | 1 (2.6) | 0 (0) | 0 (0) | 1 (6.3) |
☐ No, I continue to follow the recommendation for the AE management | 37 (97.4) | 10 (100) | 12 (100) | 15 (93.8) | |
4. Has the COVID-19 pandemic changed your treatment choice for CP-ICI in case of alternative treatments like chemotherapy, where applicable, as for clinical practice guidelines? | ☐ Yes | 4 (10.5) | 0 (0) | 2 (16.7) | 2 (12.5) |
☐ No | 34 (89.5) | 10 (100) | 10 (83.3) | 14 (87.5) | |
5. Has the COVID-19 pandemic changed your treatment choice for CP-ICI in case of alternative treatments like targeted therapy, where applicable, as for clinical practice guidelines? | ☐ Yes | 6 (15.8) | 2 (20) | 4 (33.3) | 0 (0) |
☐ No | 32 (84.2) | 8 (80) | 8 (66.7) | 16 (100) | |
6. Are the CP-ICI preferentially seen in COVID-19 clear institutions? | ☐ Yes | 14 (36.8) | 2 (20) | 7 (58.3) | 5 (31.3) |
☐ No | 24 (63.2) | 8 (80) | 5 (41.7) | 11 (68.8) | |
7. Do you use G-CSF in case of CP-ICIs with no febrile neutropenia (when used ±chemotherapy)? | ☐ Yes | 9 (23.7) | 3 (30) | 4 (33.3) | 2 (12.5) |
☐ No | 29 (76.3) | 7 (70) | 8 (66.7) | 14 (87.5) | |
8. Has this decision been changed by the COVID-19 pandemic? | ☐ Yes | 4 (10.5) | 1 (10) | 1 (8.3) | 2 (12.5) |
☐ No | 34 (89.5) | 9 (90) | 11 (91.7) | 14 (87.5) | |
9. Have the CP-ICI been managed in expert centers for immunotherapy? | ☐ Yes | 26 (68.4) | 8 (80) | 10 (83.3) | 8 (50) |
☐ No | 12 (31.6) | 2 (20) | 2 (16.7) | 8 (50) | |
10. Has this decision been changed by the COVID-19 pandemic? | ☐ Yes | 1 (2.6) | 0 (0) | 0 (0) | 1 (6.3) |
☐ No | 37 (97.4) | 10 (100) | 12 (100) | 15 (93.8) | |
11. Do you prefer to delay ICI start in lung cancer patients because of potential lung toxicity considering the high lung tropism of SARS-CoV-2 virus and its risk of ARDS? | ☐ Yes | 2 (5.3) | 0 (0) | 2 (16.7) | 0 (0) |
☐ No | 36 (94.7) | 10 (100) | 10 (83.3) | 16 (100) | |
12. In your institution, has surgery for CP been delayed because of the COVID-19 pandemic? | ☐ Yes | 16 (42.1) | 1 (10) | 9 (75) | 6 (37.5) |
☐ No | 22 (57.9) | 9 (90) | 3 (25) | 10 (62.5) |
ARDS, acute respiratory distress syndrome; CC, cancer center; CP, cancer patient; CP-ICI, cancer patients undergoing or candidate for immune checkpoint inhibitor; G-CSF, granulocyte colony stimulating factor; GH, general hospital; ICI, immune checkpoint inhibitor; N, number; UH, university hospital.